What investment strategy does Sofinnova Partners focus on?

Sofinnova Partners focuses on VC, Growth strategies in the private equity space.

How many portfolio companies does Sofinnova Partners have?

Sofinnova Partners has 107 active portfolio companies and 36 completed exits and 13 funds tracked on GP Intel.

Where is Sofinnova Partners headquartered?

Sofinnova Partners is headquartered in Paris, France.

What is Sofinnova Partners's assets under management?

Sofinnova Partners manages approximately €4.0B in assets under management.

When was Sofinnova Partners founded?

Sofinnova Partners was founded in 1997.

What sectors does Sofinnova Partners invest in?

Sofinnova Partners invests across Healthcare, Industrials.

Home/GPs/Sofinnova Partners

Sofinnova Partners

Paris, France·Founded 1997·

Venture Capital Growth Equity

·sofinnovapartners.com

Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. Founded in 1972 and based in Paris, London, and Milan, it manages over €4 billion in assets and has…Read full bio

AUM

€4.0B

Funds

Portfolio

107

SectorsHealthcareIndustrials

Key facts

HQParis, France

Founded1997

Websitesofinnovapartners.com

Recent exits

Biotech · 2025

Biotech · 2025

HealthTech · 2024

Software · 2024

Coverage notes

13 funds tracked, 143 portfolio companies (107 active · 36 realized). Verified weekly from public filings and deal announcements.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialised in life sciences with €4.0 billion of assets under management as of December 2024, headquartered in Paris with additional offices in London and Milan. Founded in 1972, the firm has backed more than 600 life sciences companies over a 53-year track record across multiple biotech, MedTech and HealthTech cycles. Sofinnova focuses exclusively on healthcare and sustainability themes, distinguishing the platform from generalist VC firms.

Investment thesis

Sofinnova deploys capital across complementary life sciences strategies including Biotech (drug discovery and development), MedTech (medical devices and digital health), HealthTech (digital health platforms) and selective Industrial Biotech and Sustainability themes. Investment stages span early-stage seed and Series A through growth equity and pre-IPO commitments, with equity tickets typically ranging from €5 million to €50 million per transaction. The platform's sector-exclusive focus enables deep scientific and clinical expertise across translational research, regulatory navigation and commercial scale-up.

Recent activity

Recent realised exits include PinCell (biotech, 2025), Verona Pharma (biotech, 2025), Amolyt Pharma (biotech, 2024), Betteromics (HealthTech, 2024) and Calliditas (biotech, 2024), reflecting strong distribution momentum across the biotech franchise. The platform tracks 13 funds, 107 active portfolio companies and 36 realised exits across a multi-decade track record. Detailed buyer names and multiple data available on Pro at €49/month.